FY2025 · ended Dec 31, 2025 · Revenue $62.90M, +699.0% YoY · Filed Mar 2, 2026
Nuvation Bio Inc. (NUVB) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $62.9 million and a net loss of $204.6 million. As of Sep 30, 2026 it held $663.4 million in cash and investments and $300.1 million in total debt.
Revenue (TTM)
$201.73M
+654.2% vs year-ago TTM
Net income (TTM)
$-135.93M
+37.5% vs year-ago TTM
Operating cash flow (TTM)
$-106.19M
+44.1% vs year-ago TTM
Free cash flow
—
EPS (TTM)
$-390.53
+39.0% vs year-ago TTM
Dividend per share
None
Shares outstanding
337.84M
+0.0% vs prior year
Net cash
$363.28M
as of Sep 30, 2026
Operating margin
-61.2%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- NUVB (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- New York, NY
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1811063
- Former names
- Panacea Acquisition Corp (until Feb 11, 2021)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $62.9M | $7.9M | — | — | — |
| Operating income | -$213.1M | -$592.6M | -$99.8M | -$119.7M | -$93.3M |
| Net income | -$204.6M | -$567.9M | -$75.8M | -$104.2M | -$86.8M |
| Diluted EPS | -$0.60 | -$2.11 | -$0.35 | -$0.48 | — |
| Operating cash flow | -$173.4M | -$130.4M | -$68.0M | -$96.1M | -$68.2M |
| Total assets | $594.8M | $540.6M | $621.5M | $672.1M | $776.2M |
| Total liabilities | $289.1M | $76.8M | $16.4M | $17.1M | $30.2M |
| Stockholders' equity | $305.7M | $463.8M | $605.1M | $655.1M | $746.0M |
| Cash and investments | $529.2M | $502.7M | $611.2M | $661.0M | $765.4M |
| Total debt | $57.4M | $8.9M | $4.0M | $4.3M | $3.1M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Results of operations
|
Nov 4, 2026 | Nov 4, 2026 |
| 10-Q | Quarterly report | Nov 4, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 6, 2026 | Aug 6, 2026 |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
New debt, Other events
|
Jul 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Material agreement, Agreement ended, New debt, Other events
|
Jun 30, 2026 | Jun 24, 2026 |
All 400 Nuvation Bio Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.